Background: NIVO + RELA fixed-dose combination (FDC), compared with NIVO alone, demonstrated a clinically meaningful benefit to progression-free survival (HR 0.79, 95% CI 0.66–0.95) and overall ...

Women are increasingly becoming a significant force in medicine, with their proportion rising from 26% in 2004 to 38% in 2022. 1 This trend extends across all medical subspecialties, with female ...

Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer Despite ...

Breast cancer is the most common cancer diagnosed in women, making it the second most commonly diagnosed cancer in the world. 1,2 About 2.3 million new breast cancer cases and 685,000 deaths occurred ...

For the purpose of this paper, we define oncology rehabilitation as services provided by licensed medical providers (eg, physical or occupational therapists, physical medicine and rehabilitation ...

Patients with advanced melanoma resistant to immune checkpoint or BRAF/MEK inhibitors have treatment options with relatively low efficacy. Lifileucel, a one-time autologous tumor-infiltrating ...

The choice of wound closure modality after limb-sparing extremity soft-tissue sarcoma (eSTS) resection is fraught with uncertainty. Leveraging machine learning and clinicoradiomic data, we developed ...

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML This phase II trial of transoral surgery (TOS) with deintensified postoperative management in human ...

Transcript. Dr. Nate Pennell: Hello, and welcome to By the Book, a monthly podcast series for ASCO Education that features engaging discussions between editors and authors from the ASCO Educational ...

The National Cancer Institute defines rare cancer as a cancer with an incidence rate <15 per 100,000 people; recently, the term “ultra-rare cancer” was defined as cancer with an incidence rate <1 × 10 ...

Over 85,000 adolescents and young adults (AYAs; age 15-39 years) are diagnosed with cancer annually in the United States, with nearly 85% expected to become long-term survivors. 1-4 Cancer survivors ...

A total of 2,697 patients were included, of which 17.4% had diabetes. The average age was 75.0 years, and most were White (80.3%). Most (85.3%) patients received androgen deprivation therapy before ...